Correction: Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin).
- DOI
- 10.1007/s13555-026-01876-x
- Published
- 2026 Aug 28
- Container
- Dermatology and therapy
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s13555-026-01876-x,
title = {Correction: Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin).},
author = {Guttman-Yassky E and Irvine AD and Gooderham M and Weidinger S and Spelman L and Silverberg JI and Crane H and ElMaraghy H and DeLuca-Carter L and Piruzeli MLB and Martimianaki G and Pierce E and Agell H and Thaçi D},
year = {2026},
journal = {Dermatology and therapy},
doi = {10.1007/s13555-026-01876-x},
url = {https://doi.org/10.1007/s13555-026-01876-x}
}RIS
TY - JOUR TI - Correction: Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin). AU - Guttman-Yassky E AU - Irvine AD AU - Gooderham M AU - Weidinger S AU - Spelman L AU - Silverberg JI AU - Crane H AU - ElMaraghy H AU - DeLuca-Carter L AU - Piruzeli MLB AU - Martimianaki G AU - Pierce E AU - Agell H AU - Thaçi D PY - 2026 JO - Dermatology and therapy DO - 10.1007/s13555-026-01876-x UR - https://doi.org/10.1007/s13555-026-01876-x ER -
APA
E, G., AD, I., M, G., S, W., L, S., JI, S., H, C., H, E., L, D., MLB, P., G, M., E, P., H, A., & D, T. (2026). Correction: Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin).. Dermatology and therapy. https://doi.org/10.1007/s13555-026-01876-x
Source records
- pubmed · retrieved 2026-09-25T10:50:11.104Z